INTRODUCTION
Colorectal cancer (CRC) is the third leading cause of cancer-related mortality in the USA. The estimated 5-year survival rates range from approximately 90% for patients with stage I disease to less than 5% for patients with stage IV disease. The cause of CRC is complex and involves the interaction between genetic and environmental factors. However, the vast majority of cases can be ascribed to environmental causes as they account for more than 70% of all incidences [1] . Recently, obesity has emerged as a leading environmental risk factor for CRC [2] [3] [4] . Due to the excessive availability of energy-dense food and physical inactivity, obesity levels have risen dramatically in the USA [5] . Indeed, the prevalence of obesity, defined by a BMI above 30 kg/m 2 , has now reached 35% with no indication of a decline [5, 6] . Whereas there is an abundance of data to support a link between obesity and CRC risk, the mechanisms responsible for this relationship have not yet been fully elucidated. This review will examine the recent literature on the possible mechanisms linking obesity to CRC. Given the space limitations, it is not intended to be a comprehensive review and rather is weighted more heavily on recent advances in the field. considered a low-grade inflammatory condition, a likely pathophysiological mechanism to link obesity to CRC risk is chronic inflammation.
Macrophages
Obesity-induced inflammation is largely mediated through quantitative and functional alterations in white adipose tissue macrophages [10, 11] . It has been reported that approximately 45-60% of adipose tissue cells express the macrophage marker F4/80 in obese mice, whereas only 10-15% of adipose tissue cells from lean mice express this marker [12] . In addition, adipose tissue macrophages exhibit a proinflammatory, classical phenotype (M1) in obese mice, whereas those from lean mice have an alternatively activated, antiinflammatory phenotype (M2) [10] . We recently reported that a high-fat diet, closely mimicking the macronutrient content of the American standard diet, can lead to increased obesity that is associated with pro-inflammatory macrophage behavior [13] . Given the propensity for adipose tissue macrophages to assume an inflammatory phenotype and the well characterized link between inflammation and CRC, it is likely that macrophages play a necessary role in the link between obesity and CRC. However, no studies have used manipulation techniques to directly determine the role of adipose tissue macrophages in the progression of this disease. Nonetheless, the current evidence for a necessary role of macrophage-induced inflammatory mediators, which are known to activate pathways that can promote CRC, is relatively strong.
Tumor necrosis factor alpha
Following excessive lipid accumulation, tumor necrosis factor alpha (TNF-a) is produced by adipose tissue macrophages and also to a lesser degree by adipocytes and preadipocytes. Although elevated TNF-a has been widely documented in adipose tissue with obesity, data on obesity-associated TNF-a in the colon are just now beginning to appear in the literature. Liu et al. [14] reported a more than 70% increase in expression and concentration of TNF-a in the colon following 17 weeks of high-fat diet feeding, which was associated with an increase in b-catenin, the key effector of Wnt signaling. In addition, an elegant study by Flores et al. [15 && ] examined the role of TNF-a on obesity-induced CRC in mice. They reported that high-fat diet feeding increased TNF-a expression in the colon that was associated with a larger number of tumors, increased proliferation, and decreased apoptosis [15 && ]. When TNF-a was inhibited, these effects were reversed; inhibition of TNF-a restored tumor number and the apoptosis/proliferation profile to levels observed in a lean mouse [15 && ]. A recent clinical study examined TNF-a, among other cytokines, in rectosigmoid mucosal biopsies of 10 obese premenopausal women before and after weight loss [16] . Weight loss (10%) was associated with a significant decrease in TNF-a concentration, indicating a reduction in colorectal inflammation [16] . However, another study reported no change in circulating levels of TNF-a in obese patients or CRC patients compared to controls [17] . Similarly, there was no relationship reported between BMI and circulating TNF-a and risk for CRC in colorectal adenoma patients [18] . Although the clinical evidence is relatively limited, the recent controlled experimental studies in rodents support a role of TNF-a in obesityenhanced CRC.
Monocyte chemoattractant protein
Monocyte chemoattractant protein (MCP)-1 has been identified as an essential chemokine for monocyte trafficking. It has been reported to contribute to tissue macrophage accumulation by inducing a chronic inflammatory state. A recent investigation transferred wild-type monocytes to MCP-1 À/À recipients and reported that adipose tissue macrophage accumulation was reduced by approximately 40%, implicating MCP-1 as a major contributory factor to monocyte migration into adipose tissue [11] . Moreover, MCP-1 has been implicated as an important
KEY POINTS
Inflammatory cytokines, adipokines, and estrogen have all emerged as potential mediators of the relationship between obesity and colorectal cancer.
Obesity-enhanced inflammation is co-ordinated by adipose tissue macrophages that secrete inflammatory cytokines including TNF-a, MCP-1, and IL-6, all of which are linked to colorectal cancer risk.
Adiponectin is decreased with obesity and has been reported to be negatively associated with colorectal cancer, whereas leptin is increased and is positively associated with the disease.
Estrogen has been shown to influence colorectal cancer, although there are some inconsistencies in the literature; however, most studies implicate estrogen receptor b as beneficial in colorectal cancer.
A better understanding of the inter-related mechanisms that link obesity to colorectal cancer risk is necessary for the design of effective treatment approaches in future clinical trials.
chemokine for macrophage recruitment in several human tumors including CRC, and has been found to be associated with increased grade of the tumor as well as poor prognosis [19, 20] . We recently reported an increase in MCP-1 in intestinal tissue in a mouse model of CRC that was positively correlated with the percentage of large polyps [21] . Subsequently, we crossed the Apc Min/þ mouse model of intestinal tumorigenesis with an MCP-1 À/À mouse to examine the role of MCP-1 in CRC [22 & ]. MCP-1 deficiency decreased overall polyp number as well as large polyp number [22 & ]. Furthermore, macrophagepositive cells were decreased in the polyp tissue and so were the expression of markers associated with M1 and M2 macrophages, as well as T-regulatory cells, whereas markers for cytotoxic T cells were increased [22 & ]. In addition, MCP-1 deficiency offset the increased expression of inflammatory mediators in polyp tissue [22 & ]. Similarly, Bailey et al. [23] has reported that MCP-1 expression is correlated with tumor-associated macrophage number and stage of CRC in humans. And recently, Hillenbrand et al. [17] reported that circulating MCP-1 was increased in both obese and CRC patients. However, a recent study showed lower MCP-1 levels in CRC patients compared to controls [24] . Although there have been no studies that have specifically examined the role of MCP-1 in obesity-enhanced CRC, the evidence in the independent models largely supports a disease-promoting effect of MCP-1 in both obesity and CRC.
Interleukin 6
Interleukin (IL)-6, an inflammatory cytokine released by adipocytes and adipose tissue macrophages during obesity, may play a role in obesityenhanced CRC [25] . In fact, epidemiological studies indicate an association between IL-6 and CRC, and controlled experiments in mice substantiate these claims [26, 27] . For example, Baltgalvis et al. [28] reported that IL-6 deficiency reduced the number of large polyps by approximately 30% in the Apc Min/þ mice, the effects of which were reversed when IL-6 was overexpressed. A recent clinical study reported that IL-6 expression is a prognostic marker of tumor behavior in stage III CRC patients [29] . Similarly, high levels of circulating IL-6 have been found to be associated with advanced CRCs [24] . Furthermore, in individuals with adenoma, plasma levels of IL-6 were positively correlated with BMI, plasma insulin levels, and insulin resistance [30 & ]. The mechanisms for IL-6-indcued tumorigenesis are thought to be mediated, at least in part, by activation of signal transducers and activators of transcription 3 (STAT3). A recent study documented increased IL-6 and p-STAT3-positive epithelial cells in patients with active ulcerative colitis compared to patients with inactive ulcerative colitis or healthy controls [31] . In addition, in dysplasia and CRC, there are significantly more epithelial cells expressing IL-6 and p-STAT3 compared with controls [31] . To our knowledge, there are no studies that have specifically examined the role of IL-6 on CRC in an obesity setting. However, it is conceivable that IL-6, which is increased with obesity, can influence CRC.
ADIPOKINES
In addition to their traditional role in energy homeostasis, adipose-derived hormones (adipokines) have been implicated as potential mediators of the effects of obesity on CRC risk. Adiponectin and leptin, two of the most abundant adipokines, are altered during adipose tissue dysfunction (i.e. obesity) and have been strongly associated with the pathogenesis of CRC.
Adiponectin
Adiponectin, an adipokine secreted exclusively by adipose tissue, is decreased in obese patients, likely increasing their propensity for the development of CRC. Several recent mechanistic studies using mice have made substantial advancement in our understanding of the role of adiponectin in CRC. For example, Saxena et al. [32] examined the effects of adiponectin deficiency on chronic inflammationinduced CRC. They reported that deficiency of adiponectin resulted in more severe symptoms along with a greater number and larger area of tumors that included higher immune cell infiltration and inflammation compared to wild-type mice [32] . Adiponectin knockout mice also showed higher secretion of the proinflammatory cytokines including IL-6, IL-1b, and TNF-a, and a reduction in the anti-inflammatory cytokine IL-10 [32] . Similarly, a recent study by Moon et al. [33 && ] precisely examined the role of adiponectin on CRC in the settings of obesity. They found that mice fed a highfat diet had larger tumors than those fed a low-fat diet, but adiponectin administration reversed this effect [33 && ]. Adiponectin treatment also suppressed angiogenesis in tumors as indicated by fewer dense microvessel areas and a reduction in mRNA expression of Vascular Endothelial Growth Factor [33 && ]. Whereas IL-12, a cytokine that has been associated with antitumor properties, was increased following adiponectin treatment, in contrast to the finding of Saxena et al., serum cytokine (IFN-g, IL-2, IL-4, IL-5, IL-10, and TNF-a) levels were unchanged [33 && ]. To further address the mechanisms for this effect, they completed a series of in-vitro studies and found that adiponectin directly controls the malignant potential, and regulates metabolic, cell cycle, and inflammatory pathways in both mouse and human colon cancer cell lines [33 && ]. Consistent with the animal studies, clinical studies also support a potential role for adiponectin in the link between obesity and CRC. A recent study reported a decrease in serum adiponectin levels in CRC patients compared to healthy controls, as well as a negative correlation between adiponectin levels and stage of disease [34] . In contrast, while Hillenbrand et al. [17] reported a decrease in adiponectin in obese patients, they found the adiponectin levels in CRC patients were not different from healthy controls. These convergent findings may result from the lack of differentiation of adiponectin fractions in these studies. Adiponectin fractions are hypothesized to have different biological activities [i.e. high-molecular-weight (HMW) adiponectin is thought to regulate insulin sensitivity, whereas non-HMW adiponectin plays a role in the inflammatory response]. In fact, Aleksandrova et al. [35 && ] reported that total adiponectin and non-HMW adiponectin concentrations were inversely associated with risk of CRC, but there was no association for HMW adiponectin. Whereas the animal studies support a role of adiponectin in CRC, investigation of the relative importance of different adiponectin fractions in CRC pathogenesis is necessary prior to the development of effective clinical therapeutic strategies.
Leptin
In contrast to adiponectin, leptin levels increase in direct proportion to body fat and thus are elevated in obese individuals. Whereas there is an abundance of literature to implicate leptin as a potential mediator between obesity and CRC, the exact mechanisms have not yet been elucidated, which is not surprising, given the inconsistencies in the literature. Nonetheless, recent studies have progressed our understanding of the role of this adipokine in CRC.
The proposed link between leptin and CRC was driven initially by studies of leptin receptor expression by various human epithelial colon cancer cell lines. When bound to leptin, the receptor can activate signal transduction pathways that are thought to enhance cell proliferation and DNA synthesis. For example, Fenton et al. [36] reported that leptin promotes the proliferation of preneoplastic (IMCE) cells. Whereas the in-vitro evidence is relatively strong, there are mixed reports among the animal studies. For instance, an earlier study reported that leptin failed to promote growth of colon cancer xenografts in nude mice and did not increase intestinal tumorigenesis in Apc Min/þ mice [37] . In contrast, a more recent study found a significant decrease of tumor cell proliferation in leptindeficient tumors, as well as a dramatic inhibition of tumor growth in leptin-deficient and leptinreceptor-deficient mice, despite the animals exhibiting severe obesity [38] . This ability of leptin to regulate CRC growth was mediated by colonic leptin signaling via the leptin receptor/signal transducer and activator of transcription 3 (STAT3) pathway, suggesting that leptin signaling is a direct pathway that is critical for CRC growth and not merely a bystander of the established relationship between obesity and CRC [38] .
Although clinical investigations have provided evidence for a link between leptin and CRC, like in the animal studies, there are some inconsistencies among findings. A recent study by Aleksandrova et al. [39 & ] examined the association of leptin and soluble leptin receptor, which has been found to regulate leptin's physiologic functions, with the risk of CRC in a prospective nested case-control study. They reported that a soluble leptin receptor was strongly and inversely associated with CRC risk, but there was no association found for leptin and CRC risk [39 & ]. And, in fact, another study reported that leptin concentrations were actually decreased in CRC patients [17] . In contrast, in a case-cohort study, it was found that leptin has an independent effect on CRC in postmenopausal women [40 & ]. On the basis of the recent literature, it is likely that leptin plays a significant role in CRC; however, additional studies are needed to confirm this relationship and to elucidate the exact mechanisms underlying these effects.
ESTROGEN
Estrogen is increased with obesity and has been shown to influence CRC, although its role remains controversial. Whereas some studies have implicated estrogen as being protective in CRC, others have suggested it to be an independent risk factor. However, recent evidence favors a protective effect of estrogen and in particular estrogen receptor-b (Erb ]. Furthermore, Erb negativity was associated with an increased hazard ratio for death, death attributed to CRC, as well as a poorer disease-free survival. Consistently, Fang et al. [44] reported that low expression of tumor Erb is a risk factor for overall survival in patients with stage II colon cancer. In addition, postmenopausal hormone therapy is associated with reduced risk of CRC [45] . In general, the current evidence supports a protective effect of estrogen, and specifically Erb, in CRC. However, the exact mechanisms have not yet been determined. And furthermore, the effect that obesity has on this relationship remains elusive.
CONCLUSION
The development of the majority of CRCs is largely influenced by nongenetic factors such as obesity. Therefore, a large body of research is now focused on understanding the molecular links between obesity and CRC risk. Whereas inflammatory mediators, adipokines, and estrogen have all been implicated as causative agents, there have been some inconsistencies in the literature and there is a dearth of evidence in the setting of obesity. Future studies should explore these mechanisms specifically in obesity models. And further, more studies should be carried out to examine interactions between these factors as it is likely that this relationship is mediated by a complex network of interrelated mechanisms.
